ISI Group Initiates Coverage of LabCorp, Quest at Neutral | GenomeWeb

NEW YORK (GenomeWeb News) – Investment firm International Strategy & Investment Group today initiated coverage of clinical laboratories Laboratory Corporation of America and Quest Diagnostics with Neutral ratings on their stock.

ISI put a price target of $110.50 on LabCorp shares and a price target of $63.00 on Quest's stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.